<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
  
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">CAR</journal-id>
      <journal-id journal-id-type="hwp">spcar</journal-id>
      <journal-title>Cartilage</journal-title>
      <issn pub-type="ppub">1947-6035</issn>
      <issn pub-type="epub">1947-6043</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.1177/1947603512455193</article-id>
      <article-id pub-id-type="publisher-id">10.1177_1947603512455193</article-id>
      <title-group>
        <article-title>Efficacy Evaluation of a New Hyaluronan Derivative HYADD<sup>®</sup> 4-G to
          Maintain Cartilage Integrity in a Rabbit Model of Osteoarthritis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" xlink:type="simple">
          <name name-style="western">
            <surname>Mainil-Varlet</surname>
            <given-names>Pierre</given-names>
          </name>
          <xref ref-type="aff" rid="aff1-1947603512455193">1</xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Schiavinato</surname>
            <given-names>Antonella</given-names>
          </name>
          <xref ref-type="aff" rid="aff2-1947603512455193">2</xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Ganster</surname>
            <given-names>Murielle Marie</given-names>
          </name>
          <xref ref-type="aff" rid="aff3-1947603512455193">3</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1-1947603512455193"><label>1</label>Aginko Research AG, Marly, Switzerland</aff>
      <aff id="aff2-1947603512455193"><label>2</label>Fidia Farmaceutici SpA, Abano Terme,
        Italy</aff>
      <aff id="aff3-1947603512455193"><label>3</label>University of Bern, Bern, Switzerland</aff>
      <author-notes>
        <corresp id="corresp1-1947603512455193">Pierre Manil-Varlet, Aginko Research AG, Route de
          l’ancienne Papeterie, 1723 Marly, Switzerland Email:
          <email xlink:type="simple">pm@aginko.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>1</month>
        <year>2013</year>
      </pub-date>
      <volume>4</volume>
      <issue>1</issue>
      <fpage>28</fpage>
      <lpage>41</lpage>
      <permissions>
        <copyright-statement>© The Author(s) 2013</copyright-statement>
        <copyright-year>2013</copyright-year>
        <copyright-holder content-type="sage">SAGE Publications</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/" xlink:type="simple">
          <p>This is an open-access article distributed under the terms of the Creative
            Commons Attribution License, which permits unrestricted use, distribution,
            and reproduction in any medium, provided the original work is properly
            cited.</p>
        </license>
      </permissions>
      <abstract>
        <p><italic>Objective</italic>: To test the efficacy of a hyaluronan derivative
            (HYADD<sup>®</sup>4-G) in a model of osteoarthritis (anterior cruciate ligament [ACLT])
          and to compare its efficacy with the injection of growth factors. <italic>Design</italic>:
          In a first experimental set-up, specially selected for treatment scheme with published
          studies on hyaluronan or growth factor efficacy in osteoarthritis, saline,
            HYADD<sup>®</sup>4-G, rh-BMP-7, and the treatments of rh-BMP-7 or rh-BMP-2 with
            HYADD<sup>®</sup>4-G were injected after ACLT, for five times starting 3 weeks after
          ACLT. Euthanasia was at day 70. The knees were evaluated by gross morphological
          observation, x-ray, and histology (Study A). In a second experimental set-up selected to
          evaluate the efficacy of three viscosupplement injections, starting 4 weeks after ACTL,
            HYADD<sup>®</sup>4-G was compared to saline (Study B). <italic>Results</italic>: (A)
          X-ray analysis showed more damage in the saline group than all other treatment groups
          (2.67 ± 0.61 for saline, 0.83 ± 0.26 for HYADD<sup>®</sup>4-G, 1.67 ± 0.82 for
            HYADD<sup>®</sup>4-G with rh-BMP-2, 0.75 ± 0.76 for HYADD<sup>®</sup>4-G with rh-BMP-7,
          and 1.58 ± 0.49 for rh-BMP-7), <italic>P</italic> &lt; 0.05. In the femoral condyle, the
          Mankin’s score for HYADD<sup>®</sup>4-G with rh-BMP-2, HYADD<sup>®</sup>4-G with rh-BMP-7,
          and rh-BMP7 alone was statistically lower compared to saline in the medial part; in the
          lateral part a significant lower value was observed in the HYADD<sup>®</sup>4-G with the
          rh-BMP-2 group. (B) The Kellgren and Lawrence score and Mankin’s score was lower in the
            HYADD<sup>®</sup>4-G group than in the saline group (<italic>P</italic> &lt; 0.002 and
            <italic>P</italic> = 0.0031). <italic>Conclusions</italic>: These two studies suggest
          that HYADD<sup>®</sup>4-G delayed the cartilage degeneration and that the association of
            HYADD<sup>®</sup>4-G with growth factors is synergistic.</p>
      </abstract>
      <kwd-group>
        <kwd>osteoarthritis</kwd>
        <kwd>hyaluronan derivative</kwd>
        <kwd>rabbit ACLT</kwd>
        <kwd>cartilage degradation</kwd>
        <kwd>growth factors</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="section1-1947603512455193" sec-type="intro">
      <title>Introduction</title>
      <p>Osteoarthritis is the most common joint disorder in the aging population. Although surgical
        treatment of osteoarthritis can reduce pain and improve joint mobility and function, the
        operative management of osteoarthritis is associated with significant cost and
        morbidity.</p>
      <p>Hyaluronic acid (HA) is a high-molecular-weight glycosaminoglycan. The average molecular
        weight of HA in synovial fluid is 4 to 5 × 10<sup>6</sup> Da.<sup><xref ref-type="bibr" rid="bibr1-1947603512455193">1</xref></sup> HA has both viscous and elastic properties,
        and the degree to which each of them predominates depends on distinct loading conditions. In
        arthritic conditions, elastoviscosity of the synovial fluid is abnormally low,<sup><xref ref-type="bibr" rid="bibr2-1947603512455193">2</xref></sup> and thus elastoviscous
        solutions of high-molecular-weight HA have been developed to be injected
            intra-articularly.<sup><xref ref-type="bibr" rid="bibr3-1947603512455193">3</xref><xref ref-type="bibr" rid="bibr4-1947603512455193"/><xref ref-type="bibr" rid="bibr5-1947603512455193"/><xref ref-type="bibr" rid="bibr6-1947603512455193"/>-<xref ref-type="bibr" rid="bibr7-1947603512455193">7</xref></sup> In 1974, the first clinical
        study showed that with this treatment the elastoviscosity of the synovial fluid returned to
        normal levels and the pain associated with the movement of the joint decreased.<sup><xref ref-type="bibr" rid="bibr3-1947603512455193">3</xref></sup> The beneficial effect of the
        therapeutic intra-articular injection of HA has been confirmed in the most recent published
        systematic review and meta-analysis.<sup><xref ref-type="bibr" rid="bibr8-1947603512455193">8</xref>,<xref ref-type="bibr" rid="bibr9-1947603512455193">9</xref></sup></p>
      <p>Currently, there are five injectable HA formulations approved for use in the United States.
        These preparations differ with respect to HA origin, method of production, treatment
        schedule, molecular weight, half-life within the joint, rheological properties,
        pharmacodynamics, and cost.<sup><xref ref-type="bibr" rid="bibr10-1947603512455193">10</xref><xref ref-type="bibr" rid="bibr11-1947603512455193"/><xref ref-type="bibr" rid="bibr12-1947603512455193"/>-<xref ref-type="bibr" rid="bibr13-1947603512455193">13</xref></sup></p>
      <p>HYADD<sup>®</sup>4-G (Fidia Farmaceutici, Abano Terme, Italy) is a novel amide derivative
        of 500 to 730 kDa HA. In this HA derivative, an aliphatic amine (hexadecylamine) is bound to
        HA at the carboxylic group of the glucuronic acid (2% substitution). HYADD<sup>®</sup>4-G is
        a hydrogel with rheological properties superior to Hyalgan<sup>®</sup> (Fidia Farmaceutici)
        and to human synovial fluid.<sup><xref ref-type="bibr" rid="bibr14-1947603512455193">14</xref></sup></p>
      <p>HYADD<sup>®</sup>4-G has shown a beneficial effect on synovial pathological changes in
        osteoarthritis. The induced increase in high-molecular-weight HA (HMWHA) synthesis and a
        decreased synovial intimal hyperplasia with fewer injections than Hyalgan treatment suggests
        potential advantages of this preparation.<sup><xref ref-type="bibr" rid="bibr15-1947603512455193">15</xref>,<xref ref-type="bibr" rid="bibr16-1947603512455193">16</xref></sup></p>
      <p>BMP-7 has been shown to up-regulate the expression of CD44, the hyaluronan receptor, as
        well as the expression of hyaluronic acid synthase-2 (HAS2)<sup><xref ref-type="bibr" rid="bibr17-1947603512455193">17</xref>,<xref ref-type="bibr" rid="bibr18-1947603512455193">18</xref></sup> and aggrecan<sup><xref ref-type="bibr" rid="bibr19-1947603512455193">19</xref></sup> by chondrocytes, resulting in enhanced
        extracellular matrix (ECM) deposition and retention.</p>
      <p>The objectives of these preclinical studies were the following:</p>
      <list id="list1-1947603512455193" list-type="order">
        <list-item>
          <p>To examine the long-term effect of one course of intra-articular injections of
              HYADD<sup>®</sup>4-G on the development of osteoarthritis induced by transection of
            the anterior cruciate ligament (ACLT) using the application (five time injections)
            tested previously with Hyalgan in the same animal model<sup><xref ref-type="bibr" rid="bibr20-1947603512455193">20</xref></sup> and to see if the combination of
            growth factors and HYADD<sup>®</sup>4-G have a synergic effect with the beginning of
            treatment in an early phase of the disease.</p>
        </list-item>
        <list-item>
          <p>To evaluate the efficacy of this new hyaluronan derivative with a treatment cycle of
            only three HYADD<sup>®</sup>4-G injections and the beginning of treatment in a more
            advanced stage (injection starting 4 weeks post-ACLT).</p>
        </list-item>
      </list>
    </sec>
    <sec id="section2-1947603512455193" sec-type="methods">
      <title>Methods</title>
      <sec id="section3-1947603512455193">
        <title>Animals</title>
        <p>Sixty-four SPF adult female white New Zealand rabbits (Charles River Laboratory,
          L’Arbresle Cedex, France) were included in the study. The animals were older than 24
          weeks.</p>
      </sec>
      <sec id="section4-1947603512455193">
        <title>Surgery and Treatment</title>
        <p>The surgical protocol was approved by the Bernese Cantonal Authorities (BE 2006/38). The
          surgery was performed under general anesthesia (induction, intramuscular: medetomidine 200
          µg/kg, climasolan 0.5 mg/kg, and fentanyl 10 µg/kg; maintenance isoflurane). The rabbit
          was placed in a left lateral position and the right operated leg was shaved and
          disinfected with Betadine solution. The knee was approached via a medial parapatellar
          incision (between the medial collateral ligament and patellar ligament). The patella was
          retracted medially by extension of the knee to expose the entire trochlea and the upper
          parts of the condyles, and the anterior cruciate ligament was transected. The patella was
          replaced gently in the trochlea groove and the incision was sutured in layers.
          Postoperatively the animals were permitted cage activity without immobilization. The
          animals were closely monitored for infections and other complications.</p>
      </sec>
      <sec id="section5-1947603512455193">
        <title>Experimental Design</title>
        <sec id="section6-1947603512455193">
          <title>Study A</title>
          <p>Group 1 (5Sal + ACTL) underwent ACTL followed by a regimen of five injections of
            saline. Group 2 (5HYADD + ACLT) underwent ACLT, followed by a course of five injections
            of HYADD<sup>®</sup>4-G at concentration 8 mg/ml (500 µl per injection). Group 3 (5BMP7
            + ACLT) underwent ACLT, followed by a course of five injections of 1 µg rh-BMP-7 (from
            R&amp;D Systems, Abingdon, UK) diluted with 500 µl phosphate-buffered saline (PBS).
            Group 4 (5HYADD/BMP-7 + ACLT) underwent ACLT, followed by a course of five injections of
            a combination of 1 µg rh-BMP-7 and 500 µl HYADD<sup>®</sup>4-G. Group 5 (5HYADD/BMP-2 +
            ACLT) underwent ACLT, followed by a course of five injections of a combination of 3 µg
            rh-BMP-2 (Reliatech, Braunschweig, Germany) and 500 µl HYADD<sup>®</sup>4-G. This group
            was added to verify also the effect of HYADD<sup>®</sup>4-G associated with a different
            rh-BMP. Rabbits were injected with those treatments 3 weeks after ACLT five times at
            10-day intervals. Six animals per group were included in Study A. This design was
            selected to compare the present study with similar preclinical studies using similar
                products.<sup><xref ref-type="bibr" rid="bibr20-1947603512455193">20</xref></sup></p>
        </sec>
        <sec id="section7-1947603512455193">
          <title>Study B</title>
          <p>Group 1 (3Sal + ACTL) underwent ACLT followed by a regimen of three injections of
            saline (500 µl per injection). Group 2 (3HYADD + ACLT) underwent ACLT, followed by a
            course of three injections of HYADD<sup>®</sup>4-G at a concentration of 8 mg/ml (500 µl
            per injection). Rabbits were injected with those treatments 4 weeks after ACLT three
            times at 10-day intervals. Seventeen animals per group were included in Study B. This
            design was selected to see if a regimen of fewer injections could still be used in a
            more advanced disease stage.</p>
          <p>All animals were euthanized 70 days after disease induction by injecting an excess dose
            of pentobarbital. At the time of sacrifice, the cartilage surfaces were photographed,
            and then the operated site was excised. The joint was subjectively evaluated for gross
            appearance of the articular cartilage (tibia and femur) and synovial membranes. The
            explants were processed by fixation.</p>
        </sec>
      </sec>
      <sec id="section8-1947603512455193">
        <title>Assessments</title>
        <p>All gross morphological, histological, and radiological analyses were performed by
          treatment-blind personnel.</p>
      </sec>
      <sec id="section9-1947603512455193">
        <title>X-Rays</title>
        <p>X-rays (Philips, Bucky Diagnost Trauma, Eindhoven, Netherlands) were taken after surgery
          and postmortem in two different planes. For Study B, x-ray evaluation was performed also
          before the beginning of the intra-articular treatment. Two plane radiographs with straight
          knees on the operated legs were taken after sacrifice. They were read by an expert
          radiologist blindly and classified according to the Kellgren and Lawrence scale<sup><xref ref-type="bibr" rid="bibr21-1947603512455193">21</xref>,<xref ref-type="bibr" rid="bibr22-1947603512455193">22</xref></sup>:</p>
        <list id="list2-1947603512455193" list-type="bullet">
          <list-item>
            <p>Grade 0, no osteophytes</p>
          </list-item>
          <list-item>
            <p>Grade 1, doubtful osteophytes</p>
          </list-item>
          <list-item>
            <p>Grade 2, minimal osteophytes, possibly with narrowing, cysts, and sclerosis</p>
          </list-item>
          <list-item>
            <p>Grade 3, moderate or definite osteophytes with moderate joint space narrowing</p>
          </list-item>
          <list-item>
            <p>Grade 4, severe with large osteophytes and definite joint space narrowing</p>
          </list-item>
        </list>
      </sec>
      <sec id="section10-1947603512455193">
        <title>Macroscopic Analysis</title>
        <p>Macroscopic cartilage assessment was performed on the knee joint. The compartments medial
          femoral condyle (MFC), lateral femoral condyle (LFC), medial tibial plateau (MTP), and
          lateral tibial plateau (LTP) were graded following India ink application. The knee
          specimens were painted with an Indian ink solution (Higgins, Waterproof India Ink,
          Standford Corp, Bellwood, IL) and then the excess ink was washed away with PBS. The
          condyles were photographed and two independent graders assessed each condyle.</p>
        <p>The samples were graded according to the Outerbridge classification<sup><xref ref-type="bibr" rid="bibr23-1947603512455193">23</xref></sup>:</p>
        <list id="list3-1947603512455193" list-type="bullet">
          <list-item>
            <p>Grade 1 = No uptake of India ink, which indicates an intact surface</p>
          </list-item>
          <list-item>
            <p>Grade 2 = Minimal focal uptake of India ink, which indicates a minimal
              fibrillation</p>
          </list-item>
          <list-item>
            <p>Grade 3 = Evident large focal dark patches of ink uptake, which indicates overt
              fibrillation</p>
          </list-item>
          <list-item>
            <p>Grade 4 = Large general uptake of India ink, which indicates erosion of cartilage</p>
          </list-item>
        </list>
      </sec>
      <sec id="section11-1947603512455193">
        <title>Histological Processing and Histopathological Observations</title>
        <p>Samples were decalcified in 10% ethylenediaminetetraacetic acid in PBS solution and
          dehydrated in ethanol/xylene prior to paraffin embedding. Two cuts were performed per
          compartments (MFC, LFC, MTP, and LTP) and stained with Safranin O-fast Green and
          hematoxylin and eosin (HE). Synovial membranes were embedded in paraffin, cut, and stained
          with HE. The cartilage surfaces were morphologically described while observing the
          cartilage and the bone compartment. Two independent pathologists evaluated the
          histological sections from each of the four compartments using a modified Mankin’s score
            (<xref ref-type="table" rid="table1-1947603512455193"><bold>Table
              1</bold></xref>).<sup><xref ref-type="bibr" rid="bibr24-1947603512455193">24</xref></sup> All the samples were scored blindly. An average of the individual
          observer scores was calculated for each knee. In addition, the synovial membranes were
          graded based on the following criteria (<xref ref-type="table" rid="table2-1947603512455193"><bold>Table 2</bold></xref>)<sup><xref ref-type="bibr" rid="bibr25-1947603512455193">25</xref></sup>: intimal hyperplasia,
          lymphocytic/plasmocytic infiltration, subintimal fibrosis, and vascularity.</p>
        <table-wrap id="table1-1947603512455193" position="float">
          <label>Table 1.</label>
          <caption>
            <p>Modified Mankin’s Histological Score for Cartilage Evaluation</p>
          </caption>
          <graphic alt-version="no" alternate-form-of="table1-1947603512455193" position="float" xlink:href="10.1177_1947603512455193-table1.tif" xlink:type="simple"/>
          <table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <tbody>
              <tr>
                <td colspan="2" rowspan="1">Cartilage structure</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Normal</td>
                <td colspan="1" rowspan="1">0</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Surface irregularities</td>
                <td colspan="1" rowspan="1">1</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Pannus and surface irregularities</td>
                <td colspan="1" rowspan="1">2</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Clefts to transitional zone</td>
                <td colspan="1" rowspan="1">3</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Clefts to radial zone</td>
                <td colspan="1" rowspan="1">4</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Clefts to calcified zone</td>
                <td colspan="1" rowspan="1">5</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Complete disorganization</td>
                <td colspan="1" rowspan="1">6</td>
              </tr>
              <tr>
                <td colspan="2" rowspan="1">Cartilage cells</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Normal</td>
                <td colspan="1" rowspan="1">0</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Pyknosis, lipid degeneration hypercellularity</td>
                <td colspan="1" rowspan="1">1</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Clusters</td>
                <td colspan="1" rowspan="1">2</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Hypocellularity</td>
                <td colspan="1" rowspan="1">3</td>
              </tr>
              <tr>
                <td colspan="2" rowspan="1">Safranin-O</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Normal</td>
                <td colspan="1" rowspan="1">0</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Slight reduction</td>
                <td colspan="1" rowspan="1">1</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Moderate reduction</td>
                <td colspan="1" rowspan="1">2</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Severe reduction</td>
                <td colspan="1" rowspan="1">3</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> No staining</td>
                <td colspan="1" rowspan="1">4</td>
              </tr>
              <tr>
                <td colspan="2" rowspan="1">Tidemark integrity</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Intact</td>
                <td colspan="1" rowspan="1">0</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Destroyed</td>
                <td colspan="1" rowspan="1">1</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <table-wrap id="table2-1947603512455193" position="float">
          <label>Table 2.</label>
          <caption>
            <p>Synovial Membrane Scoring System</p>
          </caption>
          <graphic alt-version="no" alternate-form-of="table2-1947603512455193" position="float" xlink:href="10.1177_1947603512455193-table2.tif" xlink:type="simple"/>
          <table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <tbody>
              <tr>
                <td colspan="2" rowspan="1">Intimal hyperplasia</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> 1 to 2 layers only</td>
                <td colspan="1" rowspan="1">0</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> 3 to 4 layers, focal</td>
                <td colspan="1" rowspan="1">1</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> 5 or more layers, focal</td>
                <td colspan="1" rowspan="1">2</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> 5 or more layers, diffuse</td>
                <td colspan="1" rowspan="1">3</td>
              </tr>
              <tr>
                <td colspan="2" rowspan="1">Lymphocytic/plasmocytic infiltration</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> None</td>
                <td colspan="1" rowspan="1">0</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> 1 focus of infiltration</td>
                <td colspan="1" rowspan="1">1</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> 2 to 5 foci of infiltration</td>
                <td colspan="1" rowspan="1">2</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Diffuse infiltration or &gt;5 loci</td>
                <td colspan="1" rowspan="1">3</td>
              </tr>
              <tr>
                <td colspan="2" rowspan="1">Subintimal fibrosis</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> None</td>
                <td colspan="1" rowspan="1">0</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Light focal collagenous staining</td>
                <td colspan="1" rowspan="1">1</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Heavy focal collagenous staining</td>
                <td colspan="1" rowspan="1">2</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> Heavy diffuse collagenous staining</td>
                <td colspan="1" rowspan="1">3</td>
              </tr>
              <tr>
                <td colspan="2" rowspan="1">Vascularity</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> 0 to 2 vascular elements</td>
                <td colspan="1" rowspan="1">0</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> 3 to 4 vascular elements</td>
                <td colspan="1" rowspan="1">1</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> 5 to 8 vascular elements</td>
                <td colspan="1" rowspan="1">2</td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1"> More than 8 vascular elements</td>
                <td colspan="1" rowspan="1">3</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="section12-1947603512455193">
        <title>Immunohistochemistry Analysis</title>
        <p>Immunohistochemistry (IHC) for collagen type I and collagen type II was performed as
          previously described.<sup><xref ref-type="bibr" rid="bibr26-1947603512455193">26</xref></sup> The sections were incubated overnight with a monoclonal primary
          antibody against collagen type I (Quartett, Berlin, Germany), collagen type II (II-II6B3,
          Hybridoma Bank, University of Iowa, Iowa City, IA). Bound antibodies were detected
          according to the manufacturer’s protocol, using biotinylated secondary antibody and
          streptavidin alkaline phosphatase conjugated. Visualization was performed with the
          incubation in DAKO Real detection system.</p>
        <p>The matrix intensity of the IHC samples was analyzed and graded according to a score that
          was developed for the purpose of the study. The principles are described in <xref ref-type="fig" rid="fig1-1947603512455193"><bold>Figure 1</bold></xref>. The slides were
          blindly scored according to their staining intensity by two pathologists. Score ranged
          from 1 to 6. IHC for anticollagen type II was scored for matrix intensity and cellular
          abundance. Collagen I was graded for presence or absence within the articular cartilage.
          This analysis was only conducted in Study A. Reference samples were also stained (healthy
          rabbit, nonoperated, same strain sex, and age).</p>
        <fig id="fig1-1947603512455193" position="float">
          <label>Figure 1.</label>
          <caption>
            <p>Description of the grading system used to evaluate collagen immunohistochemistry
              (IHC) cartilage samples. The collagen type II staining is quantified at the matrix
              level or at the cellular/pericellular level. The matrix is graded based on the
              staining intensity: grade 1 to 2 for low staining, grade 3 to 4 for reduced staining,
              and grade 5 to 6 for marked staining. The intensity of the pericellular cell staining
              for collagen II is graded according to the following score: from 1 to 2 if the stained
              cells are rare, 3 to 4 if clusters of stained cells are evident, 5 to 6 if the stained
              cells are abundant. Each zone superficial (I), intermediate (II), or deep (III) are
              graded individually. No tissue is left because of the degeneration process. The score
              0 is not assigned.</p>
          </caption>
          <graphic alt-version="no" position="float" xlink:href="10.1177_1947603512455193-fig1.tif" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="section13-1947603512455193">
        <title>Statistical Analysis</title>
        <p>All data are reported as the mean ± standard error of the mean. The data from x-ray and
          microscopic analysis were analyzed using nonparametric test, the Kruskal–Wallis test in
          Study A, and the Mann–Whitney test in Study B. The Bonferroni test was used when a
          significance difference was found. The immunohistochemistry data were analyzed using the
          two-way ANOVA comparison and chi-square test. <italic>P</italic> values were corrected for
          multiplicity using the Bonferroni test.</p>
      </sec>
    </sec>
    <sec id="section14-1947603512455193" sec-type="results">
      <title>Results</title>
      <sec id="section15-1947603512455193">
        <title>Macroscopic Analysis</title>
        <sec id="section16-1947603512455193">
          <title>Study A</title>
          <p>The macroscopic observation of the explanted joints revealed that a moderate to severe
            synovitis was present in all animals belonging to the saline group. In the rh-BMP-7
            group, a moderate synovitis was present in all animals. In all the other groups, the
            synovitis was not present or was evident in moderate amounts in only one or two animals
            per group. Osteophytes were present in all groups; however, in the saline group
            osteophytes were observed in larger amounts. The India ink grading of the four knee
            compartments (LFC, MFC, MTP, and LTP) was 9.67 ± 1.37 for the saline group, 8.5 ± 0.83
            for HYADD<sup>®</sup>4-G, 8.17 ± 2.13 for HYADD<sup>®</sup>4-G in combination with
            rh-BMP-2, 8.66 ± 1.21 for HYADD<sup>®</sup>4-G in combination with rh-BMP-7, and 8.5 ±
            1.76 for rh-BMP-7. These differences were not statistically significant (multiplicity
            corrected <italic>P</italic> value &lt; 0.05) (<xref ref-type="fig" rid="fig2-1947603512455193"><bold>Fig. 2</bold></xref>).</p>
          <fig id="fig2-1947603512455193" position="float">
            <label>Figure 2.</label>
            <caption>
              <p>(<bold>A</bold>) Macroscopic view of a maintained cartilage surface, no
                fibrillation of the surface after India ink. Few osteophytes are visible in the
                trochlea. Animal Allocation: HYADD4-G + BMP-7. (<bold>B</bold>) Macroscopic view of
                a deep fibrillation on the medial condyle (Grade IV) and superficial fibrillation on
                the lateral condyle. Animal allocation HYADD4-G. (<bold>C</bold>) Macroscopic view
                of bilateral erosion till the subchondral bone (Grade IV). Animal allocation:
                Saline. (<bold>D</bold>) Safranin O staining. Magnification 40×. Maintained Safranin
                O staining. No fibrillation of the surface. Light hypercellularity. No tide mark
                duplication. Animal allocation: HYADD4-G + BMP-7. (<bold>E</bold>) Safranin O
                staining, magnification 40×. Moderate lost of Safranin O, clefts to the transitional
                zone, duplication moderate of the tide mark. Animal allocation: HYADD4-G.
                  (<bold>F</bold>) Safranin O staining, magnification 40×. Severe lost of Safranin
                O, clefts to the calcified zone and loss of most of the cartilage surface. Animal
                allocation: Saline. (<bold>G</bold>) Hematoxylin–eosin (HE) staining, magnification
                10×. Absence of intimal hyperplasia, light subtimal hyperplasia. Animal allocation:
                HYADD4-G. (<bold>H</bold>) HE staining, magnification 2×. Osteophyte (*) complete
                ablation of the cartilage layer. Animal allocation: Saline. (<bold>I</bold>) HE
                staining, magnification 10×. Severe intimal hyperplasia, heavy focal subtimal
                hyperplasia, diffuse lymphocytic infiltration, and presence of vascular elements.
                Animal allocation: Saline.</p>
            </caption>
            <graphic alt-version="no" position="float" xlink:href="10.1177_1947603512455193-fig2.tif" xlink:type="simple"/>
          </fig>
        </sec>
        <sec id="section17-1947603512455193">
          <title>Study B</title>
          <p>The macroscopic observation of the explanted joints revealed that a moderate synovitis
            was present in all rabbits. Osteophytes were present in all groups. They were more
            pronounced in the saline group. The India ink grading of the four knee compartments
            analyzed (LFC, MFC, MTP, and LTP) was 15.3 ± 4.2 for the saline group and 15.5 ± 3.3 for
            the HYADD<sup>®</sup>4-G treated group. These differences were not statistically
            significant; however, a more advanced degeneration was evident when compared to Study
            A.</p>
        </sec>
      </sec>
      <sec id="section18-1947603512455193">
        <title>Radiological Analysis</title>
        <sec id="section19-1947603512455193">
          <title>Study A</title>
          <p>The radiological grading of the knees was 2.67 ± 0.61 for the saline group, 0.83 ± 0.26
            for the HYADD<sup>®</sup>4-G group, and 1.67 ± 0.82 for HYADD<sup>®</sup>4-G in
            combination with rh-BMP-2, 0.75 ± 0.76 for HYADD<sup>®</sup>4-G in combination with
            rh-BMP-7, and 1.58 ± 0.49 for the rh-BMP-7 group. There were significant differences
            between the saline group and all other groups (multiplicity corrected <italic>P</italic>
            value &lt; 0.05). Moreover the difference between HYADD<sup>®</sup>4-G in combination
            with rh-BMP-7 was also significant compared to the rh-BMP-7 group (multiplicity
            corrected <italic>P</italic> value &lt; 0.05). The average radiological score between
            these two groups suggested a synergic effect of HYADD<sup>®</sup>4-G with rh-BMP-7
              (<xref ref-type="fig" rid="fig3-1947603512455193"><bold>Fig. 3a</bold></xref>).</p>
          <fig id="fig3-1947603512455193" position="float">
            <label>Figure 3.</label>
            <caption>
              <p>X-ray analysis of the study. (<bold>a</bold>) Graphic representation of the
                Kellgren and Laurence Score of the various treatment groups at euthanasia.
                  (<bold>b</bold>) Graphic representation of the Kellgren and Laurence score of the
                various treatment groups prior the first injection and at euthanasia.</p>
            </caption>
            <graphic alt-version="no" position="float" xlink:href="10.1177_1947603512455193-fig3.tif" xlink:type="simple"/>
          </fig>
        </sec>
        <sec id="section20-1947603512455193">
          <title>Study B</title>
          <p>Before the first injection, the radiological grading of the rabbit knees were,
            respectively, 0.31 ± 0.42 for the saline group and 0.23 ± 0.60 for the
            HYADD<sup>®</sup>4-G treated group. At euthanasia, the radiological grading scores were
            3.19 ± 0.83 for the saline treated group and 2.59 ± 0.64 for the HYADD<sup>®</sup>4-G
            treated group. These results are depicted in <xref ref-type="fig" rid="fig3-1947603512455193"><bold>Figure 3b</bold></xref>. The average Kellgren and
            Laurence score of the HYADD<sup>®</sup>4-G group was statistically significantly lower
            than the control group at euthanasia (multiplicity corrected <italic>P</italic> value
            &lt; 0.002).</p>
        </sec>
      </sec>
      <sec id="section21-1947603512455193">
        <title>Histological Analysis</title>
        <p>The mean Mankin’s score for normal healthy nonoperated rabbits was 1.1 ± 0.20.</p>
        <sec id="section22-1947603512455193">
          <title>Study A</title>
          <p>The lower the modified Mankin’s score of an individual animal is the better outcome
            with respect to potential delay of further progression of an already present
            osteoarthritis. The mean modified Mankin’s score obtained by the evaluation of all the
            four compartments was 5.77 ± 1.94 in the saline group and 3.9 ± 1.38 in the
              HYADD<sup>®</sup>4-G group. The mean scores for the HYADD<sup>®</sup>4-G in
            combination with rh-BMP-2, HYADD<sup>®</sup>4-G in combination with rh-BMP-7, and
            rh-BMP-7 alone groups were, respectively, 4.53 ± 1.35, 4.9 ± 2.1, and 4.83 ± 2.05. There
            was no statistical difference between the different groups (<xref ref-type="fig" rid="fig4-1947603512455193"><bold>Fig. 4</bold></xref>).</p>
          <fig id="fig4-1947603512455193" position="float">
            <label>Figure 4.</label>
            <caption>
              <p>(<bold>A</bold>) Study A: Histological grading according to the modified Mankin’s
                score. Overall score, all knee compartments. (<bold>B</bold>) Study B: Histological
                grading according to the modified Mankin’s score. Overall score, all knee
                compartments.</p>
            </caption>
            <graphic alt-version="no" position="float" xlink:href="10.1177_1947603512455193-fig4.tif" xlink:type="simple"/>
          </fig>
          <p>However with the analysis for each different individual compartment a significant
            difference in the Mankin’s grading could be observed among the groups (<xref ref-type="fig" rid="fig5-1947603512455193"><bold>Fig. 5</bold></xref>). This
            difference was significant (multiplicity corrected <italic>P</italic> value &lt; 0.001)
            in the LFC for HYADD<sup>®</sup>4-G in combination with rh-BMP-2 in comparison to the
            others groups. In the MFC, the Mankin’s score values for HYADD<sup>®</sup>4-G in
            combination with rh-BMP-2, HYADD<sup>®</sup>4-G in combination with rh-BMP-7, and
            rh-BMP-7 alone showed statistically significant differences compared to the other groups
              (HYADD<sup>®</sup>4-G and saline) (<xref ref-type="fig" rid="fig5-1947603512455193"><bold>Fig. 5a</bold></xref>). No difference in histological analysis could be seen,
            however, between HYADD<sup>®</sup>4-G in combination with rh-BMP-7 and rh-BMP-7
            alone.</p>
          <fig id="fig5-1947603512455193" position="float">
            <label>Figure 5.</label>
            <caption>
              <p>Study A: Histological grading according to the modified Mankin’s score. Overall
                score, individual knee compartments.</p>
            </caption>
            <graphic alt-version="no" position="float" xlink:href="10.1177_1947603512455193-fig5.tif" xlink:type="simple"/>
          </fig>
          <p>In the MTP compartment, a trend in which all the treatment groups had a lower (i.e.,
            better) score compared with saline treatment was seen (<xref ref-type="fig" rid="fig5-1947603512455193"><bold>Fig. 5c</bold></xref>). This difference was only
            significant for HYADD<sup>®</sup>4-G alone and HYADD<sup>®</sup>4-G in combination with
            rh-BMP-2 compared to saline group (multiplicity corrected <italic>P</italic> value &lt;
            0.05). No significant difference was seen in the LTP (<xref ref-type="fig" rid="fig5-1947603512455193"><bold>Fig. 5d</bold></xref>).</p>
          <p>Each single parameter of the modified Mankin’s score in each treatment group is
            described in <xref ref-type="table" rid="table3-1947603512455193"><bold>Table
              3</bold></xref>. The parameters that mostly contributed in the decrease of the
            Mankin’s score were the cartilage structure and the morphological appearance of the
            cartilage cells.</p>
          <table-wrap id="table3-1947603512455193" position="float">
            <label>Table 3.</label>
            <caption>
              <p>Individual Scores of Each Category of the Modified Mankin’s Score Is Shown (Mean ±
                Standard Deviation)</p>
            </caption>
            <graphic alt-version="no" alternate-form-of="table3-1947603512455193" position="float" xlink:href="10.1177_1947603512455193-table3.tif" xlink:type="simple"/>
            <table>
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="char" char="." span="1"/>
                <col align="char" char="." span="1"/>
                <col align="char" char="." span="1"/>
                <col align="char" char="." span="1"/>
                <col align="char" char="." span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th colspan="1" rowspan="1"/>
                  <th align="center" colspan="1" rowspan="1">Cartilage Structure</th>
                  <th align="center" colspan="1" rowspan="1">Cartilage Cells</th>
                  <th align="center" colspan="1" rowspan="1">Safranin-O Staining</th>
                  <th align="center" colspan="1" rowspan="1">Tidemark Integrity</th>
                  <th align="center" colspan="1" rowspan="1">Total Average</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td colspan="1" rowspan="1">Nonoperated animal</td>
                  <td colspan="1" rowspan="1">0.50 ± 0.25</td>
                  <td colspan="1" rowspan="1">0 ± 0</td>
                  <td colspan="1" rowspan="1">0.5 ± 0.25</td>
                  <td colspan="1" rowspan="1">0 ± 0</td>
                  <td colspan="1" rowspan="1">1.0 ± 0.25</td>
                </tr>
                <tr>
                  <td colspan="6" rowspan="1">Study A</td>
                </tr>
                <tr>
                  <td colspan="1" rowspan="1"> Saline</td>
                  <td colspan="1" rowspan="1">3.57 ± 1.30</td>
                  <td colspan="1" rowspan="1">1.80 ± 0.80</td>
                  <td colspan="1" rowspan="1">2.00 ± 0.77</td>
                  <td colspan="1" rowspan="1">0.17 ± 0.23</td>
                  <td colspan="1" rowspan="1">5.77 ± 1.94</td>
                </tr>
                <tr>
                  <td colspan="1" rowspan="1"> HYADD<sup>®</sup>4-G</td>
                  <td colspan="1" rowspan="1">1.87 ± 1.13</td>
                  <td colspan="1" rowspan="1">0.90 ± 0.84</td>
                  <td colspan="1" rowspan="1">1.13 ± 0.72</td>
                  <td colspan="1" rowspan="1">0.00 ± 0.00</td>
                  <td colspan="1" rowspan="1">3.90 ± 1.38</td>
                </tr>
                <tr>
                  <td colspan="1" rowspan="1"> HYADD<sup>®</sup>4-G + BMP-2</td>
                  <td colspan="1" rowspan="1">2.13 ± 0.90</td>
                  <td colspan="1" rowspan="1">1.07 ± 0.73</td>
                  <td colspan="1" rowspan="1">1.33 ± 0.84</td>
                  <td colspan="1" rowspan="1">0.00 ± 0.00</td>
                  <td colspan="1" rowspan="1">4.53 ± 1.35</td>
                </tr>
                <tr>
                  <td colspan="1" rowspan="1"> HYADD<sup>®</sup>4-G + BMP-7</td>
                  <td colspan="1" rowspan="1">2.47 ± 1.30</td>
                  <td colspan="1" rowspan="1">0.80 ± 0.46</td>
                  <td colspan="1" rowspan="1">1.60 ± 0.57</td>
                  <td colspan="1" rowspan="1">0.03 ± 0.07</td>
                  <td colspan="1" rowspan="1">4.90 ± 2.10</td>
                </tr>
                <tr>
                  <td colspan="1" rowspan="1"> BMP-7</td>
                  <td colspan="1" rowspan="1">2.33 ± 1.26</td>
                  <td colspan="1" rowspan="1">1.07 ± 0.78</td>
                  <td colspan="1" rowspan="1">1.36 ± 0.97</td>
                  <td colspan="1" rowspan="1">0.07 ± 0.14</td>
                  <td colspan="1" rowspan="1">4.83 ± 2.05</td>
                </tr>
                <tr>
                  <td colspan="6" rowspan="1">Study B</td>
                </tr>
                <tr>
                  <td colspan="1" rowspan="1"> Saline</td>
                  <td colspan="1" rowspan="1">4.02 ± 1.11</td>
                  <td colspan="1" rowspan="1">2.11 ± 0.59</td>
                  <td colspan="1" rowspan="1">2.51 ± 0.86</td>
                  <td colspan="1" rowspan="1">0.27 ± 0.16</td>
                  <td colspan="1" rowspan="1">9.03 ± 2.12</td>
                </tr>
                <tr>
                  <td colspan="1" rowspan="1"> HYADD<sup>®</sup>4-G</td>
                  <td colspan="1" rowspan="1">3.04 ± 1.14</td>
                  <td colspan="1" rowspan="1">1.58 ± 0.63</td>
                  <td colspan="1" rowspan="1">1.90 ± 0.88</td>
                  <td colspan="1" rowspan="1">0.14 ± 0.12</td>
                  <td colspan="1" rowspan="1">6.21 ± 2.77</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
          <p>In synovial membranes, in the saline group the average inflammatory score was 6.60 ±
            2.88, whereas in the HYADD<sup>®</sup>4-G group it was 2.01 ± 1.09, in the
              HYADD<sup>®</sup>4-G + rh-BMP-2 group it was 3.40 ± 1.67, in the HYADD<sup>®</sup>4-G
            + rh-BMP-7 group it was 1.67 ± 1.36, and in the rh-BMP-7 alone group it was 4.33 ± 1.86.
            The differences were significant (multiplicity corrected <italic>P</italic> value &lt;
            0.05) in the HYADD<sup>®</sup>4-G, HYADD<sup>®</sup>4-G + rh-BMP-2, and
              HYADD<sup>®</sup>4-G + rh-BMP-7 groups compared to saline. The combination of rh-BMP-7
            with HYADD<sup>®</sup>4-G gave a significantly better result than the growth factor
            alone in term of inflammatory response. Representative histological pictures are shown
            in <xref ref-type="fig" rid="fig2-1947603512455193"><bold>Figures 2</bold></xref> and
              <xref ref-type="fig" rid="fig7-1947603512455193"><bold>7</bold></xref>.</p>
          <fig id="fig6-1947603512455193" position="float">
            <label>Figure 6.</label>
            <caption>
              <p>Study B: Histological grading according to the modified Mankin’s score. Overall
                score, individual knee compartments.</p>
            </caption>
            <graphic alt-version="no" position="float" xlink:href="10.1177_1947603512455193-fig6.tif" xlink:type="simple"/>
          </fig>
          <fig id="fig7-1947603512455193" position="float">
            <label>Figure 7.</label>
            <caption>
              <p>(<bold>A</bold>) Representative histological pictures (best, average, worst) of the
                study groups in Study A. Typical x-ray representation of Study A. (<bold>B</bold>)
                Representative histological pictures (best, average, worst) of the study groups in
                Study B. Typical x-ray representation of study B.</p>
            </caption>
            <graphic alt-version="no" position="float" xlink:href="10.1177_1947603512455193-fig7.tif" xlink:type="simple"/>
          </fig>
        </sec>
        <sec id="section23-1947603512455193">
          <title>Study B</title>
          <p>The modified Mankin’s score was 9.02 ± 2.12 for the saline treated group and 6.21 ±
            2.77 for the HYADD<sup>®</sup>4-G treated group. The difference was statistically
            significant (multiplicity corrected <italic>P</italic> value = 0.0031). These data are
            summarized in <xref ref-type="fig" rid="fig4-1947603512455193"><bold>Figures
              4b</bold></xref> and <xref ref-type="fig" rid="fig6-1947603512455193"><bold>6</bold></xref>. Representative histological pictures are shown in <xref ref-type="fig" rid="fig7-1947603512455193"><bold>Figure 7</bold></xref>.</p>
          <p>The individual scores of each category of the modified Mankin’s score for the treatment
            groups are presented in <xref ref-type="table" rid="table3-1947603512455193"><bold>Table
                3</bold></xref>.</p>
          <p>The individual score component of the Mankin’s grading system between saline and
              HYADD<sup>®</sup>4-G groups were not statistically significant, although the saline
            treated group had a tendency toward higher values. Furthermore, individual anatomical
            compartment was analyzed separately. Among the analyzed compartments (LFC anterior, MFC
            anterior, LFC posterior, MFC posterior, LTP posterior, and MTP posterior), only LTP
            posterior showed a significant difference between saline and HYADD<sup>®</sup>4-G groups
            (multiplicity corrected <italic>P</italic> value = 0.0098) (<xref ref-type="fig" rid="fig7-1947603512455193"><bold>Fig. 7</bold></xref>).</p>
          <p>In the synovial membranes, the mean synovial membrane score was 4.6 ± 0.94 for the
            saline group and 3.9 ± 1.5 for the HYADD<sup>®</sup>4-G group. The difference was not
            statistically significant. Representative histological pictures are shown in <xref ref-type="fig" rid="fig2-1947603512455193"><bold>Figure 2</bold></xref>.</p>
        </sec>
      </sec>
      <sec id="section24-1947603512455193">
        <title>Immunohistological Analysis</title>
        <p>In normal healthy nonoperated rabbits, the mean intensity for matrix staining was 4.0 ±
          0.2 at the superficial level, 4.8 ± 0.4 in the intermediate zone, and 4.6 ± 0.3 in the
          deep zone. The score for pericellular collagen II staining was 4.5 ± 0.6 at the
          superficial level, 3.8 ± 0.4 at the intermediate level, and 3.3 ± 0.4 in the deep level.
          Results of the immunohistochemistry are presented in <xref ref-type="fig" rid="fig8-1947603512455193"><bold>Figure 8</bold></xref>.</p>
        <fig id="fig8-1947603512455193" position="float">
          <label>Figure 8.</label>
          <caption>
            <p>Immunohistological grading anticollagen II (Study A). The graph represents the matrix
              staining intensity and the cellular abundance score according to a grading system (see
                <xref ref-type="fig" rid="fig1-1947603512455193"><bold>Fig. 1</bold></xref>).</p>
          </caption>
          <graphic alt-version="no" position="float" xlink:href="10.1177_1947603512455193-fig8.tif" xlink:type="simple"/>
        </fig>
        <sec id="section25-1947603512455193">
          <title>IHC of collagen II: Matrix intensity</title>
          <p>At level III, just above the tidemark, there were significant differences (decrease of
            the collagen staining intensity) between the control and saline (<italic>P</italic> &lt;
            0.01), control versus HYADD<sup>®</sup>4-G (<italic>P</italic> &lt; 0.05), control
            versus HYADD<sup>®</sup>4-G + rh-BMP-2 (<italic>P</italic> &lt; 0.05), control versus
            HYADD4-G–® + rh-BMP-7 (<italic>P</italic> &lt; 0.05), and control versus rh-BMP-7
              (<italic>P</italic> &lt; 0.05). All the other comparisons were not statistically
            significant (<italic>P</italic> &gt; 0.05). All treatments had a positive effect at
            level II, although statistically not significant in comparison to the saline-treated
            group.</p>
        </sec>
        <sec id="section26-1947603512455193">
          <title>IHC of collagen II: Cellular abundance</title>
          <p>No statistical significant difference could be observed among treatment and control
            groups (<xref ref-type="fig" rid="fig8-1947603512455193"><bold>Fig.
            8</bold></xref>).</p>
        </sec>
        <sec id="section27-1947603512455193">
          <title>IHC of collagen I</title>
          <p>In the rh-BMP-7 group, there was a tendency to detect more frequently collagen type I.
            Chi-square test however revealed no statistically significant differences among the
            treatment groups (data not shown).</p>
        </sec>
      </sec>
    </sec>
    <sec id="section28-1947603512455193" sec-type="discussion">
      <title>Discussion</title>
      <p>It has been hypothesized that intra-articular HA application causes analgesia by increasing
        the elastoviscosity of the intercellular matrix of soft tissues around the joint, thus
        providing a rheological buffer that reduces the force transmitted during joint movements to
        the transducing membrane elements at sensory nerve terminals innervating the synovial lining
        and capsule.<sup><xref ref-type="bibr" rid="bibr27-1947603512455193">27</xref><xref ref-type="bibr" rid="bibr28-1947603512455193"/><xref ref-type="bibr" rid="bibr29-1947603512455193"/>-<xref ref-type="bibr" rid="bibr30-1947603512455193">30</xref></sup></p>
      <p>The exact mechanism of action in osteoarthritis is however still to be entirely defined,
        but it is proven that intra-articular HA reduces pain through its effect on peripheral pain
        receptors, increasing the viscoelastic properties of synovial fluid.<sup><xref ref-type="bibr" rid="bibr31-1947603512455193">31</xref></sup></p>
      <p>Several R&amp;D programs are devoted to the chemical modification of HA through coupling or
        cross-linking to enhance both the molecular weight and the half-life of the injected HA.
        These reactions increase the HA molecular weight and, consequently, its viscoelastic
        features, while preserving its biocompatibility.<sup><xref ref-type="bibr" rid="bibr32-1947603512455193">32</xref></sup></p>
      <p>Hyalgan<sup>®</sup> is constituted by 500 to 730 kDa average-molecular-weight HA and has a
        very low elastic modulus.<sup><xref ref-type="bibr" rid="bibr14-1947603512455193">14</xref></sup> HYADD<sup>®</sup>4-G is a hydrogel of HA of the same molecular weight but
        chemically modified with hexadecylamine bound to the glucuronic acid, at a low degree of
        substitution (2% mol/mol), thus rendering this HA derivative more viscous and
            elastic.<sup><xref ref-type="bibr" rid="bibr14-1947603512455193">14</xref></sup> In a
        previous study, it was shown that HYADD<sup>®</sup>4-G is effective in reducing the
        excitatory effects of moderate and strong mechanical forces on the impulse activity in fine
        medial articular nerve afferents of the guinea pig knee joint.<sup><xref ref-type="bibr" rid="bibr33-1947603512455193">33</xref></sup></p>
      <p>The HA treatment efficacy is long lasting with improvement of symptoms up to 6 months also
        with a single intra-articular treatment.<sup><xref ref-type="bibr" rid="bibr34-1947603512455193">34</xref></sup></p>
      <p><italic>In vitro</italic> and <italic>in vivo</italic> studies have provided evidence that
        this natural polymer prevents cartilage degradation and the relevance of the HA molecular
            weight.<sup><xref ref-type="bibr" rid="bibr11-1947603512455193">11</xref></sup> In
        osteoarthritic chondrocyte culture the IL-1β induced synthesis of matrix metalloproteinase
        13 (MMP-13) is inhibited by the preincubation with HMWHA,<sup><xref ref-type="bibr" rid="bibr35-1947603512455193">35</xref></sup> on the contrary the presence of HA
        oligosaccharides induces in chondrocyte culture MMP-13 synthesis.<sup><xref ref-type="bibr" rid="bibr36-1947603512455193">36</xref></sup> Growing preclinical and clinical evidences
        support the notion that, in addition to relieving the symptoms of osteoarthritis, HA
        modifies the structure of diseased joint, at least early in the evolution of the disease
            process.<sup><xref ref-type="bibr" rid="bibr37-1947603512455193">37</xref></sup></p>
      <p>Intra-articular injections of growth factors in osteoarthritis have been considered a
        therapeutic option as a disease modifying drug in osteoarthritis since the early
            1990s.<sup><xref ref-type="bibr" rid="bibr38-1947603512455193">38</xref></sup></p>
      <p>One of the most promising growth factor for the intra-articular treatment of osteoarthritis
        seems to be rh-BMP-7, already in the clinical phase in osteoarthritic patients.<sup><xref ref-type="bibr" rid="bibr39-1947603512455193">39</xref></sup> Recent preclinical studies
        have already demonstrated the efficacy of rh-BMP-7 injections in osteoarthritis,<sup><xref ref-type="bibr" rid="bibr40-1947603512455193">40</xref><xref ref-type="bibr" rid="bibr41-1947603512455193"/>-<xref ref-type="bibr" rid="bibr42-1947603512455193">42</xref></sup> but because of the quick release of the proteins from the articular
        joints the preclinical studies evaluating the efficacy in osteoarthritis treatment were
        performed with intra-articular injections every week from the induction of osteoarthritis or
        at concluded osteoarthritis with the continuous delivery of the growth factor via a minipump
        applied in the joint or with weekly injections.</p>
      <p>To the best of our knowledge, these are the first preclinical results of a combination
        therapy of a highly morphogenic stimulus for the cartilage, that is, rh-BMP-7 and a new
        hydrogel HA derivative in an osteoarthritis animal model.</p>
      <p>The histological analysis in the individual compartments revealed a significant progression
        of osteoarthritis in the various compartments 10 weeks after ACLT with the more severe
        changes in the medial condyle. A statistically lower Mankin’s score was seen for rh-BMP-7
        alone, rh-BMP-7 in combination with HYADD<sup>®</sup>4-G, or rh-BMP-2 in combination with
          HYADD<sup>®</sup>4-G. A statistically significant decreased cartilage damage for the joint
        treated with HYADD<sup>®</sup>4-G alone was seen, however, in the medial tibial compartment.
        The results indicate that both HYADD<sup>®</sup>4-G and the growth factor rh-BMP-7 alone
        reduce the cartilage damage in some of the analyzed cartilage compartments, but the
        association of HYADD<sup>®</sup>4-G and growth factor (rh-BMP-7 or even rhBMP-2) determined
        a significant reduction in cartilage damage in three (i.e., LFC, MFC, MTP) of the four
        analyzed cartilage compartments. Radiographically but not histologically a reduction of the
        osteoarthritis development could be seen with the combination of HYADD<sup>®</sup>4-G and
        rh-BMP-7 compared with rh-BMP-7 alone.</p>
      <p>Similarly, the synovial membrane analysis revealed a significant decrease in inflammation
        in all treatment groups employing HYADD<sup>®</sup>4-G alone or in combination therapy. The
        collagen II content in the saline group was more severely affected in the basal layer than
        the other treatment groups.</p>
      <p>A diminished anabolic response of osteoarthritis chondrocytes to growth factors has been
        shown for IGF-1.<sup><xref ref-type="bibr" rid="bibr43-1947603512455193">43</xref></sup>
        Rogachefsky <italic>et al</italic>.<sup><xref ref-type="bibr" rid="bibr38-1947603512455193">38</xref></sup> demonstrated the efficacy of IGF-1 intra-articular injection only when
        combined with intramuscular injection of sodium pentosan polysulfate, a semisynthetic drug
        inhibiting aggrecanase activity.</p>
      <p>A modulation of chondrocyte’s response to growth factors could be demonstrated in an
        experiment in which the response of chondrocytes to BMP-7 could be restored when those
        chondrocytes were submitted to hyaluronan.<sup><xref ref-type="bibr" rid="bibr44-1947603512455193">44</xref></sup> Osteoarthritis chondrocytes cannot
        maintain the balance between ECM synthesis and ECM degradation. The composition of the ECM,
        chondrocytes surface receptor density, and cytosolic signaling cascade influence the way
        chondrocytes respond to those growth factor’s stimuli. If this is true that is not solely
        the concentration of the growth factor that modulate the cell response.<sup><xref ref-type="bibr" rid="bibr44-1947603512455193">44</xref></sup></p>
      <p>Hyaluronic acid therefore plays an important role in the cell response to BMP-7 but also
        other growth factors, which can explain why a combination of HA and growth factors can be
        beneficial for intra-articular injection.</p>
      <p>The efficacy of the viscosupplementation treatment with this novel HA hydrogel treatment
        was further confirmed in our second study with only three intra-articular injections. The
        better results demonstrated in this second study with a significant improvement in the
        overall Mankin’s score, obtained by the analysis of all the analyzed cartilage compartments,
        is probably related to the higher number of animals and higher cartilage damage.</p>
      <p>In conclusion, from our pilot study, it appears that viscoelastic HA hydrogel associated to
        growth factors have better beneficial effects on the progression of osteoarthritis than the
        viscosupplement agent alone in this specific animal model of rabbit ACLT. The synergistic
        effect of viscosupplementation and growth factors need however to be further evaluated in a
        larger animal study with analysis at longer time points and evaluation of treatment effect
        also on bone changes. The use of growth factors for osteoarthritis treatment is only at the
        initial phase of clinical development and the beneficial long-term effects to be proven,
        with regard to the risk/benefit ratio, although viscosupplementation therapy has long been
        use in clinical practice and has provided evidence of long-term benefit and
            safety.<sup><xref ref-type="bibr" rid="bibr13-1947603512455193">13</xref></sup></p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="financial-disclosure">
        <label>Acknowledgments and Funding</label>
        <p>The author(s) disclosed receipt of the following financial support for the research,
          authorship, and/or publication of this article: This study was funded by Fidia
          Farmaceutici S.p.A Abano Terme, Italy.</p>
      </fn>
      <fn fn-type="conflict">
        <label>Declaration of Conflicting Interests</label>
        <p>The author(s) declared no potential conflicts of interest with respect to the research,
          authorship, and/or publication of this article.</p>
      </fn>
      <fn fn-type="other">
        <label>Ethical Approval</label>
        <p>The surgical protocol and its execution were approved by the Bernese Cantonal Authorities
          (BE 2006/38) (Animal safety committee).</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-1947603512455193">
        <label>1.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Balazs</surname><given-names>EA</given-names></name>
            <name name-style="western"><surname>Denlinger</surname><given-names>JL</given-names></name>
          </person-group>. <article-title>Viscosupplementation: a new concept in the treatment of
            osteoarthritis</article-title>. <source>J Rheumatol Suppl</source>.
            <year>1993</year>;<volume>39</volume>:<fpage>3</fpage>-<lpage>9</lpage>.</citation>
      </ref>
      <ref id="bibr2-1947603512455193">
        <label>2.</label>
        <citation citation-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Balazs</surname><given-names>EA</given-names></name>
          </person-group>. <article-title>The physical properties of synovial fluid and the special
            role of hyaluronan acid</article-title>. In: <person-group person-group-type="editor">
            <name name-style="western"><surname>Helfet</surname><given-names>A</given-names></name>
          </person-group>, editor. <source>Disorders of the knee</source>.
            <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>J. B.
            Lippincott</publisher-name>; <year>1982</year>. p.
          <fpage>61</fpage>-<lpage>74</lpage>.</citation>
      </ref>
      <ref id="bibr3-1947603512455193">
        <label>3.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Balazs</surname><given-names>EA</given-names></name>
            <name name-style="western"><surname>Denlinger</surname><given-names>JL</given-names></name>
          </person-group>. <article-title>Clinical uses of hyaluronan</article-title>. <source>Ciba
            Found Symp</source>
          <year>1989</year>;<volume>143</volume>:<fpage>265</fpage>-<lpage>75</lpage>.</citation>
      </ref>
      <ref id="bibr4-1947603512455193">
        <label>4.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Altman</surname><given-names>RD</given-names></name>
          </person-group>. <article-title>Intra-articular sodium hyaluronate in osteoarthritis of
            the knee</article-title>. <source>Semin Arthritis Rheum</source>.
            <year>2000</year>;<volume>2</volume>(<supplement>Suppl
            1</supplement>):<fpage>11</fpage>-<lpage>8</lpage>.</citation>
      </ref>
      <ref id="bibr5-1947603512455193">
        <label>5.</label>
        <citation citation-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Adams</surname><given-names>ME</given-names></name>
          </person-group>. <article-title>Viscosupplementation as articular therapy.
            Perspective</article-title>. In: <person-group person-group-type="editor">
            <name name-style="western"><surname>Laurent</surname><given-names>T</given-names></name>
          </person-group>, editor. <source>The chemistry, biology and medical applications of
            hyaluronan and its derivatives</source>. <publisher-loc>London</publisher-loc>:
            <publisher-name>Portland Press</publisher-name>; <year>1996</year>. p.
            <fpage>243</fpage>-<lpage>53</lpage>.</citation>
      </ref>
      <ref id="bibr6-1947603512455193">
        <label>6.</label>
        <citation citation-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Weiss</surname><given-names>C</given-names></name>
          </person-group>. <article-title>Hyaluronan and hylan in the treatment of
            osteoarthritis</article-title>. In: <person-group person-group-type="editor">
            <name name-style="western"><surname>Kennedy</surname><given-names>JF</given-names></name>
            <name name-style="western"><surname>Phillips</surname><given-names>GO</given-names></name>
            <name name-style="western"><surname>Williams</surname><given-names>PA</given-names></name>
            <name name-style="western"><surname>Hascall</surname><given-names>VC</given-names></name>
          </person-group>, editors. <source>Hyaluronan</source>.
            <publisher-loc>Cambridge</publisher-loc>: <publisher-name>Woodhead</publisher-name>;
            <year>2002</year>. p. <fpage>467</fpage>-<lpage>82</lpage>.</citation>
      </ref>
      <ref id="bibr7-1947603512455193">
        <label>7.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Balazs</surname><given-names>EA</given-names></name>
          </person-group>. <article-title>Analgesic effect of elastoviscous hyaluronan solutions and
            the treatment of arthritic pain</article-title>. <source>Cells Tissues Organs</source>.
            <year>2003</year>;<volume>174</volume>:<fpage>49</fpage>-<lpage>62</lpage>.</citation>
      </ref>
      <ref id="bibr8-1947603512455193">
        <label>8.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Peyron</surname><given-names>JG</given-names></name>
            <name name-style="western"><surname>Balazs</surname><given-names>EA</given-names></name>
          </person-group>. <article-title>Preliminary clinical assessment of Na-hyaluronate
            injection into human arthritic joints</article-title>. <source>Pathol Biol
            (Paris)</source>.
            <year>1974</year>;<volume>22</volume>:<fpage>731</fpage>-<lpage>6</lpage>.</citation>
      </ref>
      <ref id="bibr9-1947603512455193">
        <label>9.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Bannuru</surname><given-names>RR</given-names></name>
            <name name-style="western"><surname>Natov</surname><given-names>NS</given-names></name>
            <name name-style="western"><surname>Dasi</surname><given-names>UR</given-names></name>
            <name name-style="western"><surname>Schmid</surname><given-names>CH</given-names></name>
            <name name-style="western"><surname>McAlindon</surname><given-names>TE</given-names></name>
          </person-group>. <article-title>Therapeutic trajectory following intra-articular
            hyaluronic acid injection in knee osteoarthritis-meta-analysis</article-title>.
            <source>Osteoarthritis Cartilage</source>.
            <year>2011</year>;<volume>19</volume>(<issue>6</issue>):<fpage>611</fpage>-<lpage>9</lpage>.</citation>
      </ref>
      <ref id="bibr10-1947603512455193">
        <label>10.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Moreland</surname><given-names>LW</given-names></name>
          </person-group>. <article-title>Intra-articular hyaluronan (hyaluronic acid) and hylans
            for the treatment of osteoarthritis: mechanism of action</article-title>.
            <source>Arthritis Res Ther</source>.
            <year>2003</year>;<volume>5</volume>(<issue>2</issue>):<fpage>54</fpage>-<lpage>67</lpage>.</citation>
      </ref>
      <ref id="bibr11-1947603512455193">
        <label>11.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Ghosh</surname><given-names>P</given-names></name>
            <name name-style="western"><surname>Guidolin</surname><given-names>D</given-names></name>
          </person-group>. <article-title>Potential mechanism of action of intra-articular
            hyaluronan therapy in osteoarthritis: are the effects molecular weight
            dependent?</article-title>
          <source>Semin Arthritis Rheum</source>.
            <year>2002</year>;<volume>32</volume>:<fpage>10</fpage>-<lpage>37</lpage>.</citation>
      </ref>
      <ref id="bibr12-1947603512455193">
        <label>12.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Altman</surname><given-names>RD</given-names></name>
            <name name-style="western"><surname>Moskowitz</surname><given-names>R</given-names></name>
          </person-group>. <article-title>Intraarticular sodium hyaluronate (Hyalgan) in the
            treatment of patients with osteoarthritis of the knee: a randomized clinical
            trial</article-title>. <source>Hyalgan Study Group. J Rheumatol</source>.
            <year>1998</year>;<volume>25</volume>(<issue>11</issue>):<fpage>2203</fpage>-<lpage>12</lpage>.</citation>
      </ref>
      <ref id="bibr13-1947603512455193">
        <label>13.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Bellamy</surname><given-names>N</given-names></name>
            <name name-style="western"><surname>Campbell</surname><given-names>J</given-names></name>
            <name name-style="western"><surname>Robinson</surname><given-names>V</given-names></name>
            <name name-style="western"><surname>Gee</surname><given-names>T</given-names></name>
            <name name-style="western"><surname>Bourne</surname><given-names>R</given-names></name>
            <name name-style="western"><surname>Wells</surname><given-names>G</given-names></name>
          </person-group>. <article-title>Viscosupplementation for the treatment of osteoarthritis
            of the knee</article-title>. <source>Cochrane Database Syst Rev</source>.
            <year>2006</year>;(<issue>2</issue>):<fpage>CD005321</fpage>.</citation>
      </ref>
      <ref id="bibr14-1947603512455193">
        <label>14.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Borzacchiello</surname><given-names>A</given-names></name>
            <name name-style="western"><surname>Mayol</surname><given-names>L</given-names></name>
            <name name-style="western"><surname>Schiavinato</surname><given-names>A</given-names></name>
            <name name-style="western"><surname>Ambrosio</surname><given-names>L</given-names></name>
          </person-group>. <article-title>Effect of hyaluronic acid amide derivative on equine
            synovial fluid viscoelasticity</article-title>. <source>J Biomed Mater Res A</source>.
            <year>2010</year>;<volume>92</volume>(<issue>3</issue>):<fpage>1162</fpage>-<lpage>70</lpage>.</citation>
      </ref>
      <ref id="bibr15-1947603512455193">
        <label>15.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Smith</surname><given-names>MM</given-names></name>
            <name name-style="western"><surname>Cake</surname><given-names>MA</given-names></name>
            <name name-style="western"><surname>Ghosh</surname><given-names>P</given-names></name>
            <name name-style="western"><surname>Schiavinato</surname><given-names>A</given-names></name>
            <name name-style="western"><surname>Read</surname><given-names>RA</given-names></name>
            <name name-style="western"><surname>Little</surname><given-names>CB</given-names></name>
          </person-group>. <article-title>Significant synovial pathology in a meniscectomy model of
            osteoarthritis: modifications by intra-articular hyaluronan therapy</article-title>.
            <source>Rheumatology (Oxford)</source>.
            <year>2008</year>;<volume>47</volume>(<issue>8</issue>):<fpage>1172</fpage>-<lpage>8</lpage>.</citation>
      </ref>
      <ref id="bibr16-1947603512455193">
        <label>16.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Cake</surname><given-names>MA</given-names></name>
            <name name-style="western"><surname>Read</surname><given-names>R</given-names></name>
            <name name-style="western"><surname>Edwards</surname><given-names>S</given-names></name>
            <name name-style="western"><surname>Smith</surname><given-names>MM</given-names></name>
            <name name-style="western"><surname>Burkardt</surname><given-names>D</given-names></name>
            <name name-style="western"><surname>Little</surname><given-names>C</given-names></name>
            <etal/>
          </person-group>. <article-title>Changes in gait after bilateral meniscectomy in sheep:
            effect of two hyaluronan preparations</article-title>. <source>J Orthop Sci</source>.
            <year>2008</year>;<volume>13</volume>(<issue>6</issue>):<fpage>514</fpage>-<lpage>23</lpage>.</citation>
      </ref>
      <ref id="bibr17-1947603512455193">
        <label>17.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Nishida</surname><given-names>Y</given-names></name>
            <name name-style="western"><surname>Knudson</surname><given-names>CB</given-names></name>
            <name name-style="western"><surname>Kuettner</surname><given-names>KE</given-names></name>
            <name name-style="western"><surname>Knudson</surname><given-names>W</given-names></name>
          </person-group>. <article-title>Osteogenic protein-1 promotes the synthesis and retention
            of extracellular matrix within bovine articular cartilage and chondrocyte
            cultures</article-title>. <source>Osteoarthritis Cartilage</source>.
            <year>2000</year>;<volume>8</volume>:<fpage>127</fpage>-<lpage>36</lpage>.</citation>
      </ref>
      <ref id="bibr18-1947603512455193">
        <label>18.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Nishida</surname><given-names>Y</given-names></name>
            <name name-style="western"><surname>Knudson</surname><given-names>CB</given-names></name>
            <name name-style="western"><surname>Eger</surname><given-names>W</given-names></name>
            <name name-style="western"><surname>Kuettner</surname><given-names>KE</given-names></name>
            <name name-style="western"><surname>Knudson</surname><given-names>W</given-names></name>
          </person-group>. <article-title>Osteogenic protein-1 stimulates cell-associated matrix
            assembly by normal human articular chondrocytes</article-title>. <source>Arthritis
            Rheum</source>.
            <year>2000</year>;<volume>43</volume>:<fpage>206</fpage>-<lpage>14</lpage>.</citation>
      </ref>
      <ref id="bibr19-1947603512455193">
        <label>19.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Flechtenmacher</surname><given-names>J</given-names></name>
            <name name-style="western"><surname>Huch</surname><given-names>K</given-names></name>
            <name name-style="western"><surname>Thonar</surname><given-names>EJMA</given-names></name>
            <name name-style="western"><surname>Mollenhauer</surname><given-names>J</given-names></name>
            <name name-style="western"><surname>Davies</surname><given-names>SR</given-names></name>
            <name name-style="western"><surname>Schmid</surname><given-names>TM</given-names></name>
            <etal/>
          </person-group>. <article-title>Recombinant human osteogenic protein 1 is a potent
            stimulator of the synthesis of cartilage proteoglycans and collagens by human articular
            chondrocytes. Arthritis Rheum</article-title>.
            <year>1996</year>;<volume>39</volume>:<fpage>478</fpage>-<lpage>88</lpage>.</citation>
      </ref>
      <ref id="bibr20-1947603512455193">
        <label>20.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Amiel</surname><given-names>D</given-names></name>
            <name name-style="western"><surname>Toyoguchi</surname><given-names>T</given-names></name>
            <name name-style="western"><surname>Kobayashi</surname><given-names>K</given-names></name>
            <name name-style="western"><surname>Bowden</surname><given-names>K</given-names></name>
            <name name-style="western"><surname>Amiel</surname><given-names>ME</given-names></name>
            <name name-style="western"><surname>Healey</surname><given-names>RM</given-names></name>
          </person-group>. <article-title>Long-term effect of sodium hyaluronate (Hyalgan) on
            osteoarthritis progression in a rabbit model</article-title>. <source>Osteoarthritis
            Cartilage</source>.
            <year>2003</year>;<volume>11</volume>(<issue>9</issue>):<fpage>636</fpage>-<lpage>43</lpage>.</citation>
      </ref>
      <ref id="bibr21-1947603512455193">
        <label>21.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Ozlem Nisbet</surname><given-names>H</given-names></name>
            <name name-style="western"><surname>Ozak</surname><given-names>A</given-names></name>
            <name name-style="western"><surname>Yardimci</surname><given-names>C</given-names></name>
            <name name-style="western"><surname>Nisbet</surname><given-names>C</given-names></name>
            <name name-style="western"><surname>Yarim</surname><given-names>M</given-names></name>
            <name name-style="western"><surname>Bayrak</surname><given-names>IK</given-names></name>
            <etal/>
          </person-group>. <article-title>Evaluation of bee venom and hyaluronic acid in the
            intra-articular treatment of osteoarthritis in an experimental rabbit model. Res Vet
            Sci</article-title>.
            <year>2012</year>;<volume>93</volume>(<issue>1</issue>):<fpage>488</fpage>-<lpage>93</lpage>.</citation>
      </ref>
      <ref id="bibr22-1947603512455193">
        <label>22.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Rijk</surname><given-names>PC</given-names></name>
            <name name-style="western"><surname>de Rooy</surname><given-names>TP</given-names></name>
            <name name-style="western"><surname>Coerkamp</surname><given-names>EG</given-names></name>
            <name name-style="western"><surname>Bernoski</surname><given-names>FP</given-names></name>
            <name name-style="western"><surname>van Noorden</surname><given-names>CJ</given-names></name>
          </person-group>. <article-title>Radiographic evaluation of the knee joint after meniscal
            allograft transplantation. An experimental study in rabbits</article-title>.
            <source>Knee Surg Sports Traumatol Arthrosc</source>.
            <year>2002</year>;<volume>10</volume>:<fpage>241</fpage>-<lpage>6</lpage>.</citation>
      </ref>
      <ref id="bibr23-1947603512455193">
        <label>23.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Outerbridge</surname><given-names>RE</given-names></name>
          </person-group>. <article-title>The etiology of chondromalacia patellae</article-title>.
            <source>J Bone Joint Surg Br</source>.
            <year>1962</year>;<volume>43</volume>:<fpage>752</fpage>-<lpage>7</lpage>.</citation>
      </ref>
      <ref id="bibr24-1947603512455193">
        <label>24.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Mankin</surname><given-names>HJ</given-names></name>
            <name name-style="western"><surname>Dorfman</surname><given-names>H</given-names></name>
            <name name-style="western"><surname>Lippiello</surname><given-names>L</given-names></name>
          </person-group>. <article-title>Biochemical and metabolic abnormalities in articular
            cartilage from osteo-arthritic human hips. II Correlation of morphology with biochemical
            and metabolic data</article-title>. <source>J Bone Joint Surg Am</source>.
            <year>1971</year>;<volume>53</volume>(<issue>3</issue>):<fpage>523</fpage>-<lpage>37</lpage>.</citation>
      </ref>
      <ref id="bibr25-1947603512455193">
        <label>25.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Cake</surname><given-names>MA</given-names></name>
            <name name-style="western"><surname>Smith</surname><given-names>MM</given-names></name>
            <name name-style="western"><surname>Young</surname><given-names>AA</given-names></name>
            <name name-style="western"><surname>Ghosh</surname><given-names>P</given-names></name>
            <name name-style="western"><surname>Read</surname><given-names>RA</given-names></name>
          </person-group>. <article-title>Synovial pathology in an ovine model of osteoarthristis:
            effect of intraarticular hyaluronan (Hyalgan)</article-title>. <source>Clin Exp
            Rheumatol</source>.
            <year>2008</year>;<volume>26</volume>(<issue>4</issue>):<fpage>561</fpage>-<lpage>7</lpage>.</citation>
      </ref>
      <ref id="bibr26-1947603512455193">
        <label>26.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Giovannini</surname><given-names>S</given-names></name>
            <name name-style="western"><surname>Diaz-Romero</surname><given-names>J</given-names></name>
            <name name-style="western"><surname>Aigner</surname><given-names>T</given-names></name>
            <name name-style="western"><surname>Mainil-Varlet</surname><given-names>P</given-names></name>
            <name name-style="western"><surname>Nesic</surname><given-names>D</given-names></name>
          </person-group>. <article-title>Population doublings and percentage of S100-positive cells
            as predictors of in vitro chondrogenicity of expanded human articular
            chondrocytes</article-title>. <source>J Cell Physiol</source>.
            <year>2010</year>;<volume>222</volume>(<issue>2</issue>):<fpage>411</fpage>-<lpage>20</lpage>.</citation>
      </ref>
      <ref id="bibr27-1947603512455193">
        <label>27.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Pozo</surname><given-names>MA</given-names></name>
            <name name-style="western"><surname>Balazs</surname><given-names>EA</given-names></name>
            <name name-style="western"><surname>Belmonte</surname><given-names>C</given-names></name>
          </person-group>. <article-title>Reduction of sensory responses to passive movements of
            inflamed knee joints by hylan, a hyaluronan derivative</article-title>. <source>Exp
            Brain Res</source>.
            <year>1997</year>;<volume>116</volume>:<fpage>3</fpage>-<lpage>9</lpage>.</citation>
      </ref>
      <ref id="bibr28-1947603512455193">
        <label>28.</label>
        <citation citation-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Pawlak</surname><given-names>M</given-names></name>
          </person-group>. <article-title>Mechanoprotective actions of elastoviscous hylans on
            articular pain receptors</article-title>. In: <person-group person-group-type="editor">
            <name name-style="western"><surname>Kennedy</surname><given-names>JF</given-names></name>
            <name name-style="western"><surname>Phillips</surname><given-names>GO</given-names></name>
            <name name-style="western"><surname>Williams</surname><given-names>PA</given-names></name>
            <name name-style="western"><surname>Hascall</surname><given-names>VC</given-names></name>
          </person-group>, editors. <source>Hyaluronan</source>.
            <publisher-loc>Cambridge</publisher-loc>: <publisher-name>Woodhead</publisher-name>;
            <year>2002</year>. p. <fpage>341</fpage>-<lpage>52</lpage>.</citation>
      </ref>
      <ref id="bibr29-1947603512455193">
        <label>29.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Gomis</surname><given-names>A</given-names></name>
            <name name-style="western"><surname>Pawlak</surname><given-names>M</given-names></name>
            <name name-style="western"><surname>Balazs</surname><given-names>EA</given-names></name>
            <name name-style="western"><surname>Schmidt</surname><given-names>RF</given-names></name>
            <name name-style="western"><surname>Belmonte</surname><given-names>C</given-names></name>
          </person-group>. <article-title>Effects of different molecular weight elastoviscous
            hyaluronan solutions on articular nociceptive afferents</article-title>.
            <source>Arthritis Rheum</source>.
            <year>2004</year>;<volume>50</volume>(<issue>1</issue>):<fpage>314</fpage>-<lpage>26</lpage>.</citation>
      </ref>
      <ref id="bibr30-1947603512455193">
        <label>30.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Gomis</surname><given-names>A</given-names></name>
            <name name-style="western"><surname>Miralles</surname><given-names>A</given-names></name>
            <name name-style="western"><surname>Schmidt</surname><given-names>RF</given-names></name>
            <name name-style="western"><surname>Belmonte</surname><given-names>C</given-names></name>
          </person-group>. <article-title>Nociceptive nerve activity in an experimental model of
            knee joint osteoarthritis of the guinea pig: effect of intra-articular hyaluronan
            application</article-title>. <source>Pain</source>.
            <year>2007</year>;<volume>130</volume>:<fpage>126</fpage>-<lpage>36</lpage>.</citation>
      </ref>
      <ref id="bibr31-1947603512455193">
        <label>31.</label>
        <citation citation-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Belmonte</surname><given-names>C</given-names></name>
            <name name-style="western"><surname>Pozo</surname><given-names>MA</given-names></name>
            <name name-style="western"><surname>Balazs</surname><given-names>EA</given-names></name>
          </person-group>. <article-title>Modulation by hyaluronan and its derivatives (hylans) of
            sensory nerve activity signalling articular pain</article-title>. In: <person-group person-group-type="editor">
            <name name-style="western"><surname>Laurent</surname><given-names>TC</given-names></name>
          </person-group>, editor. <source>The chemistry, biology and medical applications of
            hyaluronan and its derivatives</source>. <publisher-loc>London</publisher-loc>:
            <publisher-name>Portland Press</publisher-name>; <year>1998</year>. p.
            <fpage>205</fpage>-<lpage>17</lpage>.</citation>
      </ref>
      <ref id="bibr32-1947603512455193">
        <label>32.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Prestwich</surname><given-names>GD</given-names></name>
            <name name-style="western"><surname>Kuo</surname><given-names>JW</given-names></name>
          </person-group>. <article-title>Chemically modified HA for therapy and regenerative
            medicine</article-title>. <source>Curr Pharm Biotechnol</source>.
            <year>2008</year>;<volume>9</volume>(<issue>4</issue>):<fpage>242</fpage>-<lpage>5</lpage>.</citation>
      </ref>
      <ref id="bibr33-1947603512455193">
        <label>33.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Gomis</surname><given-names>A</given-names></name>
            <name name-style="western"><surname>Miralles</surname><given-names>A</given-names></name>
            <name name-style="western"><surname>Schmidt</surname><given-names>RF</given-names></name>
            <name name-style="western"><surname>Belmonte</surname><given-names>C</given-names></name>
          </person-group>. <article-title>Intra-articular injections of hyaluronan solutions of
            different elastoviscosity reduce nociceptive nerve activity in a model of osteoarthritic
            knee joint of the guinea pig</article-title>. <source>Osteoarthritis Cartilage</source>.
            <year>2009</year>;<volume>17</volume>(<issue>6</issue>):<fpage>798</fpage>-<lpage>804</lpage>.</citation>
      </ref>
      <ref id="bibr34-1947603512455193">
        <label>34.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Chevalier</surname><given-names>X</given-names></name>
            <name name-style="western"><surname>Jerosch</surname><given-names>J</given-names></name>
            <name name-style="western"><surname>Goupille</surname><given-names>P</given-names></name>
            <name name-style="western"><surname>van Dijk</surname><given-names>N</given-names></name>
            <name name-style="western"><surname>Luyten</surname><given-names>FP</given-names></name>
            <name name-style="western"><surname>Scott</surname><given-names>DL</given-names></name>
            <etal/>
          </person-group>. <article-title>Single, intra-articular treatment with 6 ml hylan G-F 20
            in patients with symptomatic primary osteoarthritis of the knee: a randomized,
            multicentre, double-blind, placebo controlled trial</article-title>. <source>Ann Rheum
            Dis</source>.
            <year>2010</year>;<volume>69</volume>(<issue>1</issue>):<fpage>113</fpage>-<lpage>9</lpage>.</citation>
      </ref>
      <ref id="bibr35-1947603512455193">
        <label>35.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Julovi</surname><given-names>SM</given-names></name>
            <name name-style="western"><surname>Ito</surname><given-names>H</given-names></name>
            <name name-style="western"><surname>Nishitani</surname><given-names>K</given-names></name>
            <name name-style="western"><surname>Jackson</surname><given-names>CJ</given-names></name>
            <name name-style="western"><surname>Nakanura</surname><given-names>T</given-names></name>
          </person-group>. <article-title>Hyaluronan inhibits matrix metalloproteinase-13 in human
            arthritic chondrocytes via CD44 and P38</article-title>. <source>J Orthop Res</source>.
            <year>2011</year>;<volume>29</volume>(<issue>2</issue>):<fpage>258</fpage>-<lpage>64</lpage>.</citation>
      </ref>
      <ref id="bibr36-1947603512455193">
        <label>36.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Ohno</surname><given-names>S</given-names></name>
            <name name-style="western"><surname>Im</surname><given-names>HJ</given-names></name>
            <name name-style="western"><surname>Knudson</surname><given-names>CB</given-names></name>
            <name name-style="western"><surname>Knudson</surname><given-names>W</given-names></name>
          </person-group>. <article-title>Hyaluronan oligosaccharides induce matrix
            metalloproteinase 13 via transcriptional activation of NFkappaB and p38MAP kinase in
            articular chondrocytes</article-title>. <source>J Biol Chem</source>.
            <year>2006</year>;<volume>281</volume>(<issue>26</issue>):<fpage>17952</fpage>-<lpage>60</lpage>.</citation>
      </ref>
      <ref id="bibr37-1947603512455193">
        <label>37.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Goldberg</surname><given-names>VM</given-names></name>
            <name name-style="western"><surname>Buckwalter</surname><given-names>JA</given-names></name>
          </person-group>. <article-title>Hyaluronans in the treatment of osteoarthritis of the
            knee: evidence for disease-modifying activity</article-title>. <source>Osteoarthritis
            Cartilage</source>.
            <year>2005</year>;<volume>13</volume>:<fpage>216</fpage>-<lpage>24</lpage>.</citation>
      </ref>
      <ref id="bibr38-1947603512455193">
        <label>38.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Rogachefsky</surname><given-names>RA</given-names></name>
            <name name-style="western"><surname>Dean</surname><given-names>DD</given-names></name>
            <name name-style="western"><surname>Howell</surname><given-names>DS</given-names></name>
            <name name-style="western"><surname>Altman</surname><given-names>RD</given-names></name>
          </person-group>. <article-title>Treatment of canine osteoarthritis with insulin-like
            growth factor-1 (IGF-1) and sodium pentosan polysulfate</article-title>.
            <source>Osteoarthritis Cartilage</source>.
            <year>1993</year>;<volume>1</volume>(<issue>2</issue>):<fpage>105</fpage>-<lpage>14</lpage>.</citation>
      </ref>
      <ref id="bibr39-1947603512455193">
        <label>39.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Hunter</surname><given-names>DJ</given-names></name>
            <name name-style="western"><surname>Picke</surname><given-names>MC</given-names></name>
            <name name-style="western"><surname>Jonas</surname><given-names>BL</given-names></name>
            <name name-style="western"><surname>Kissin</surname><given-names>E</given-names></name>
            <name name-style="western"><surname>Krop</surname><given-names>J</given-names></name>
            <name name-style="western"><surname>McAlindon</surname><given-names>T</given-names></name>
          </person-group>. <article-title>Phase 1 safety and tolerability study of BMP-7 in
            symptomatic knee osteoarthritis</article-title>. <source>BMC Musculoskelet
            Disord</source>. <year>2010</year>;<volume>11</volume>:<fpage>232</fpage>.</citation>
      </ref>
      <ref id="bibr40-1947603512455193">
        <label>40.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Badlani</surname><given-names>N</given-names></name>
            <name name-style="western"><surname>Inoue</surname><given-names>A</given-names></name>
            <name name-style="western"><surname>Healey</surname><given-names>R</given-names></name>
            <name name-style="western"><surname>Coutts</surname><given-names>R</given-names></name>
            <name name-style="western"><surname>Amiel</surname><given-names>D</given-names></name>
          </person-group>. <article-title>The protective effect of OP-1 on articular cartilage in
            the development of osteoarthritis</article-title>. <source>Osteoarthritis
            Cartilage</source>.
            <year>2008</year>;<volume>16</volume>(<issue>5</issue>):<fpage>600</fpage>-<lpage>6</lpage>.</citation>
      </ref>
      <ref id="bibr41-1947603512455193">
        <label>41.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Badlani</surname><given-names>N</given-names></name>
            <name name-style="western"><surname>Oshima</surname><given-names>Y</given-names></name>
            <name name-style="western"><surname>Healey</surname><given-names>R</given-names></name>
            <name name-style="western"><surname>Coutts</surname><given-names>R</given-names></name>
            <name name-style="western"><surname>Amiel</surname><given-names>D</given-names></name>
          </person-group>. <article-title>Use of morphogenic protein-7 as a treatment for
            osteoarthritis</article-title>. <source>Clin Orthop Relat Res</source>.
            <year>2009</year>;<volume>467</volume>(<issue>12</issue>):<fpage>3221</fpage>-<lpage>9</lpage>.</citation>
      </ref>
      <ref id="bibr42-1947603512455193">
        <label>42.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Hayashi</surname><given-names>M</given-names></name>
            <name name-style="western"><surname>Muneta</surname><given-names>T</given-names></name>
            <name name-style="western"><surname>Takahashi</surname><given-names>T</given-names></name>
            <name name-style="western"><surname>Ju</surname><given-names>YI</given-names></name>
            <name name-style="western"><surname>Tsuji</surname><given-names>K</given-names></name>
            <name name-style="western"><surname>Sekiya</surname><given-names>I</given-names></name>
          </person-group>. <article-title>Intra-articular injections of bone morphogenetic protein-7
            retard progression of existing cartilage degeneration</article-title>. <source>Orthop
            Res</source>.
            <year>2010</year>;<volume>28</volume>(<issue>11</issue>):<fpage>1502</fpage>-<lpage>6</lpage>.</citation>
      </ref>
      <ref id="bibr43-1947603512455193">
        <label>43.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Loeser</surname><given-names>RF</given-names></name>
            <name name-style="western"><surname>Shanker</surname><given-names>RG</given-names></name>
            <name name-style="western"><surname>Carlson</surname><given-names>CS</given-names></name>
            <name name-style="western"><surname>Gardin</surname><given-names>JF</given-names></name>
            <name name-style="western"><surname>Shelton</surname><given-names>BJ</given-names></name>
            <name name-style="western"><surname>Sonntag</surname><given-names>WE</given-names></name>
          </person-group>. <article-title>Reduction in the chondrocyte response to insulin-like
            growth factor 1 in aging and osteoarthritis: studies in a non human primate model of
            naturally occurring disease</article-title>. <source>Arthritis Rheum</source>.
            <year>2000</year>;<volume>43</volume>(<issue>9</issue>):<fpage>1916</fpage>-<lpage>26</lpage>.</citation>
      </ref>
      <ref id="bibr44-1947603512455193">
        <label>44.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western"><surname>Andhare</surname><given-names>RA</given-names></name>
            <name name-style="western"><surname>Takahashi</surname><given-names>N</given-names></name>
            <name name-style="western"><surname>Knudson</surname><given-names>W</given-names></name>
            <name name-style="western"><surname>Knudson</surname><given-names>CB</given-names></name>
          </person-group>. <article-title>Hyaluronan promotes the chondrocyte response to
            BMP-7</article-title>. <source>Osteoarthritis Cartilage</source>.
            <year>2009</year>;<volume>17</volume>(<issue>7</issue>):<fpage>906</fpage>-<lpage>16</lpage>.</citation>
      </ref>
    </ref-list>
  </back>
</article>